News

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
Moderna plans to lay off 10% of workforce to cut costs
Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of ...
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Moderna lays off 500 in latest cost-cutting move
The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...
Moderna: RSV Upside Slim, Cash Burn Heavy
Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...
Moderna will lay off 10% of employees, Massachusetts-based company announces
Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Moderna plans to slash 10% of workforce as COVID shot sales slow
Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...
Moderna to lay off 10% of workforce
Moderna CEO Stephane Bancel said in a memo to employees that the company expects to reduce its workforce to fewer than 5,000 ...
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...